News Release 

Deep Longevity to present on aging biomarkers for clinical trials at Metabesity

Deep Longevity scientists to present a new integrated system of multiple deep biomarkers of aging and longevity at Metabesity one of the industry's

Deep Longevity Ltd

Scientific Meeting Announcement

Tuesday, September 15, 2020 (9AM EST), Deep Longevity, recently acquired by Regent Pacific (HK:0575), a company developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels today announced that its Chief Science Officer, Dr. Polina Mamoshina will present the research on deep aging clocks at Metabesity 2020, one of the largest conferences bridging aging research and metabolic diseases. Dr. Mamoshina will present on Tuesday, October 13, in Session 12 entitled "Clinical Translation - Biological Clocks and Other Biomarkers of Aging for Product Development and Regulatory Approval".

In addition, Alex Zhavorokov, PhD, the Chief Longevity Officer of Deep Longevity and CEO of Insilico Medicine will participate in Session 17 "Business - Emerging Companies", as well as two presentations, one on each company, on October 15th on the Emerging Company Showcase.

Quote from Thomas Seoh on Metabesity and Deep Aging Clocks:

"The aging biomarkers space is advancing at an explosive rate due to molecular, cellular and systems biology, Big Data and AI, and a rapidly growing body of empirical findings. The technology behind Deep Longevity and Insilico Medicine has been a driving force, and we look forward to Polina and Alex sharing their vision of the role of deep aging clocks in research, development and commercialization of products and services for healthy longevity," said Thomas Seoh, CEO of Kinexum, a co-organizer of the conference.

Deep Longevity scientists are the original inventors of the "deep aging clocks", multimodal biomarkers of aging developed using deep learning techniques with multiple granted patents. They recently published deep hematological aging clocks, deep transcriptomic and proteomic aging clocks, deep microbiomic aging clocks, and contributed to the development of the photographic aging clocks.

Metabesity, despite an unusual name evoking metabolism and obesity, refers to a constellation of chronic diseases, from diabetes and obesity to cardiovascular and neurodegenerative diseases, cancer and the aging process itself, with common metabolic roots, that thus may be susceptible to common solutions. The conference, organized by Kinexum and the Kitalys Institute and co-chaired by Professor Lawrence Steinman of Stanford and Dr. Alexander Fleming of Kinexum, brings together some of the top thought leaders from government, academia, and industry to accelerate the translation of emerging geroscience into material, accessible gains in public health, via the prevention or delay of chronic diseases and the extension of healthspan.

"In my opinion, aging clocks and explainable Deep Aging Clocks learning on multiple data types are among the most important innovations in aging research over the past decade. Modern deep learning techniques allow us not only to predict the biological age accurately or in an application-specific way. Previously I coined the term "longevity bottleneck" - a weak area in the patient's body that leads to premature death even if the other areas may function significantly longer. Deep aging clocks allow us to find and understand these longevity bottlenecks - areas that constrain and limit the organismal longevity even when effective longevity interventions may work on the other areas that may allow people to live longer. At Metabesity I would like to discuss the concept of the longevity bottlenecks and the role of AI in finding and eliminating these longevity bottlenecks ", said Alex Zhavoronkov, PhD, the founder, and CEO of Deep Longevity and Insilico Medicine.


About Deep Longevity

Deep Longevity has been acquired by Regent Pacific (HK:0575), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) (?) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

About Regent Pacific (HK: 0575)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness, and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.